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Optimizing Hepatitis C Virus (HCV) Treatment in a US 
Colocated HCV/Opioid Agonist Therapy Program
Jackie Habchi,1 Aurielle M. Thomas,2 Sophie Sprecht-Walsh,1 Elenita Arias,1 Jeffrey Bratberg,2 Linda Hurley,1 Susan Hart,1 and Lynn E. Taylor3,
1CODAC Behavioral Healthcare, Providence, Rhode Island, USA, 2University of Rhode Island, Providence, Rhode Island, USA, and 3CODAC Behavioral Healthcare and University of Rhode Island, 
Providence, Rhode Island, USA
Background. A minority of patients with opioid use disorder are treated for hepatitis C virus infection (HCV). While colocated 
HCV and opioid agonist therapy (OAT) along with harm reduction can facilitate prevention and cascade to cure, there are few real-
world examples of such embedded care models in the United States in the direct-acting antiviral (DAA) era.
Methods. We conducted a retrospective chart review to determine sustained virologic response (SVR) and reinfection rates 
during the first 5-year period of DAA availability among individuals tested and treated on-site at Rhode Island’s only nonprofit meth-
adone maintenance program.
Results. Of 275 who initiated DAAs, the mean age (range) was 43 (22–71) years, 34.5% were female, 57.5% had genotype 1a, 
23.3% had cirrhosis, and 92% were Medicaid recipients. SVR was 85.0% (232/273), while modified intent-to-treat SVR was 93.2% 
(232/249); 17 patients did not achieve SVR, 2 awaited SVR 12 weeks post-end-of-treatment, and 24 were lost to follow-up. Thirty 
reinfections were identified over 375.5 person-years of follow-up (rate, 7.99/100 person-years). The median time to first reinfec-
tion (interquartile range) was 128 (85.25–202.5) days. Before July 1, 2018, 72 patients accessed DAAs over 3.7 years; after Medicaid 
DAA restrictions were lifted, 109 patients accessed DAAs over 1.3 years. The Prior Authorization (PA) process requires many steps, 
differing across 11 RI insurers, taking 45–120 minutes per patient.
Conclusions. DAA treatment was effective among a marginalized population in an urban colocated OAT/HCV program. 
Removing DAA restrictions facilitates treatment initiation. The PA process remains a modifiable barrier to expanding capacity in 
the United States.
Keywords.  colocated care; direct-acting antivirals (DAAs); hepatitis C virus infection (HCV); opioid agonist therapy (OAT); 
people who inject drugs (PWID).
To achieve hepatitis C virus infection (HCV) elimination, a 
greater proportion of people who inject drugs (PWID) living 
with HCV need to be diagnosed, treated, and cured. PWID 
constitute the largest group of persons in the United States in-
fected with HCV and account for most new infections [1]. 
PWID may be successfully treated with direct-acting antiviral 
(DAA) agents. Contemporary meta-analyses demonstrate high 
sustained virologic response (SVR) rates among PWID with or 
without opioid agonist therapy (OAT; methadone [μ-receptor full 
agonist] and buprenorphine [μ-receptor partial agonist]) [2, 3]. 
While national and international guidelines support HCV treat-
ment scale-up for PWID, in the United States, a minority receive 
treatment.
Historically, HCV care has been delivered in specialist set-
tings. Embedding HCV treatment into services utilized by 
PWID can facilitate access, as drug-involved populations may 
face stigma and difficulty navigating traditional health care en-
vironments. The advent of DAAs simplifies HCV therapy and 
enables prescription by a broad range of providers. Delivering 
all elements of care under 1 roof may be accomplished with 
colocated HCV and addiction care.
More than four out of five PWID predominantly inject opi-
oids, making HCV treatment integration at OAT programs 
essential [4]. OAT, the key treatment for opioid use disorder 
(OUD), reduces illicit opioid use, withdrawal symptoms, and 
opioid-related morbidity and mortality [5]. OAT facilitates 
HCV screening, treatment initiation and SVR, and reduces in-
cidence and reinfection [4, 6–8]. Administering DAAs in con-
junction with OAT and high-coverage needle syringe programs 
(NSPs) establishes the optimal preventive strategy [5, 9–11].
Rhode Island (RI), ranked 10th in the nation for overdose 
deaths, reported 26 000 individuals with OUD in 2016 [12, 13]. 
A 2014 study conducted before considering the opioid crisis es-
timated 16 768 HCV-infected Rhode Islanders [14]. The work 
presented was developed given concerns that referral to off-site 
subspecialty care was failing a vulnerable population.
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METHODS
Study Design
We conducted a retrospective chart review of all patients treated 
on-site for HCV from November 1, 2014, to October 31, 2019, at 
CODAC Behavioral Health Inc. (CODAC), RI’s only nonprofit 
methadone maintenance program (MMP). CODAC runs 9 ge-
ographically dispersed sites providing OAT to >2500 patients. 
The largest, in Providence, serves 1000 patients daily, a disen-
franchised population with high rates of homelessness, pov-
erty, and frequent incarceration. Included in this review were 
patients (1) on OAT at 1 of CODAC’s 8 community sites (the 
ninth, a prison/jail, was excluded because patients receive HCV 
care in corrections) and (2) attending at least 1 HCV visit at 
CODAC Providence. Patients were not financially compensated 
for care, nor were they contacted for data collection purposes. 
The University of RI’s Institutional Review Board approved this 
research.
Colocated Care Model
CODAC Providence’s HCV Clinic started on May 1, 2014, with 
a part-time addiction, HIV, and viral hepatitis–trained internal 
medicine physician, an addiction and viral hepatitis–trained 
nurse, and a phlebotomist. CODAC Providence uses SMART 
Software for methadone dispensing, with paper charts for HCV 
care. For the first 4 years, CODAC Providence offered HCV an-
tibody testing; with a reactive result, blood was drawn for HCV 
RNA. On May 1, 2018, CODAC Providence began universal, 
opt-out, serum HCV antibody screening with reflexive RNA and 
genotype upon entry into OAT care, with annual rescreening 
for HCV-uninfected patients (Figure  1). Phlebotomy also in-
cluded testing for HIV, hepatitis A virus (HAV), and hepatitis B 
virus (HBV) serologies, liver panel, complete blood count, cre-
atinine, prothrombin time/international normalized ratio, and 
rapid plasma reagin plus urine gonorrhea and chlamydia.
The nurse navigates HCV-infected patients to an on-site 
HCV physician visit, provides viral hepatitis and harm reduc-
tion (HR) education, refers to NSP, supplies naloxone, and 
coordinates clinic flow. The initial physician visit includes a 
full medical history and physical exam, as many patients do 
not have primary care providers, along with viral hepatitis, 
HIV, polysubstance use, and prevention counseling. If history, 
physical exam, aspartate transaminase (AST)-to-platelet ratio 
index (APRI) and Fibrosis-4 (FIB-4) yield discordant results, 
Fibrosure  (LabCorp, Research Triangle Park, NorthCarolina) is 
ordered. DAAs are prescribed at visit completion (unless selec-
tion is influenced by Fibrosure result). The physician provides 
care for HIV, HBV, other sexually transmitted infections, and 
cirrhosis, prescribes HIV pre-exposure prophylaxis (PrEP), 
and addresses urgent medical concerns. She attempts to link 
patients with primary care given that CODAC is not an ambu-
latory care center but a federally licensed MMP, organization-
ally and physically separate from mainstream health care [15]. 
For women of childbearing potential, the physician provides 
preconception counseling, recommends planned pregnancies 
and avoidance during DAA therapy, and assists with contracep-
tion. Patients with cirrhosis are referred to off-site ultrasound 
for hepatocellular carcinoma (HCC) and esophageal variceal 
surveillance (albeit few make these appointments) with on-site 
serum alpha-fetoprotein biannually. On-site HAV and HBV 
vaccination began in December 2018.
Patients are accommodated through scheduled and walk-in 
visits and may remain in care no matter the number of late or 
missed visits. HCV treatment is universal, except for those with 
a short life expectancy unable to be remediated by DAAs. For 
patients without stable housing, DAA pharmacy deliveries are 
accepted and stored on-site. With their approval, patients are 
put “on hold” at the methadone window; a nurse sees a SMART 
alert to “hold” the dose until conferring with the HCV nurse. 
The nurse then reminds the patient of an HCV-related appoint-
ment and/or phlebotomy. Patients are encouraged to bring in 
injecting partners for simultaneous treatment. Deliveries of 
DAAs are provided for patients who are hospitalized or incar-
cerated midtreatment.
In July 2018, a pharmacist joined the team to lead the DAA 
Prior Authorization (PA) process. Prescribing DAAs requires 
completing and faxing a PA form, plus supporting laboratory 
results, to each patient’s insurer. There are 11 distinct RI in-
surers, each with different PA requirements and a unique PA 
form. The documentation and approval process takes 45 to 
120 minutes per patient. PAs require repeat blood tests—HCV 
RNA and genotype within 90 days even for patients with docu-
mented viremia for years and recent genotyping, prescribed 
pan-genotypic regimens—and myriad administrative elements 
(phone calls, peer-to-peer discourse, responding to denials). 
Each payer dictates a preferred pharmacy, some mail order only, 
and a preferred DAA formulary. The pharmacist also obtains 
Simplified co-located test to treat OAT/HCV pathway
Nurse navigates patient to initial HCV physician vist
Enter care at OAT clinic:
• Universal (opt-out) HCV Ab screening with reflex
   RNA and genotype
• HAV, HBV, HIV serologies
• Liver panel
• CBC, Cr, PT/INR, RPR, urine GC/ chlamydia
2nd vist: HCV treatment initiation
SVR
1st vist: HCV physician evaluation, DAAs ordered
prior authorization (PA) submitted
Figure 1. Simplified colocated test to treat OAT/HCV pathway.
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medication lists, assists with drug–drug interactions, calls in 
approved prescriptions, coordinates with numerous pharma-
cies to expedite DAA acquisition, ensure that refills are obtained 
on time as DAAs are dispensed monthly, supports adherence, 
and maintains the clinic database.
The second visit is treatment initiation, held once the payer 
approves DAAs, typically within 3 weeks. For women of child-
bearing potential, urine pregnancy testing is performed to en-
sure a negative result. The first DAA dose is witnessed. Snacks 
are supplied to patients who contend with food insecurity and 
cannot eat before DAAs that require food. Individualized plans 
are developed regarding when patients will take DAAs, storage, 
refills, and HR. During treatment, patients may see the nurse 
or doctor with questions 5 days per week. Given the substantial 
prevalence of ongoing injection and polysubstance use, the staff 
recommends that patients see the physician or nurse at week 2 
for discussing adherence, liver panel to gauge biochemical re-
sponse, and HCV RNA. Liver panel and HCV RNA are checked 
at end of treatment (EOT) and post-treatment week 12, with ad-
ditional laboratory monitoring and check-ins for patients with 
medical risk. SVR visits focus on next health steps, prioritizing 
tobacco cessation. Prompt retreatment is offered following re-
infection. Reinfection visits afford opportunity to evaluate for 
other infectious consequences of injection drug use (IDU), 
PrEP, and OAT dose evaluation.
Medicaid DAA Restrictions
Until July 1, 2018, RI Medicaid restricted DAAs to patients 
with Meta-Analysis of Histologic Data in Viral Hepatitis 
(METAVIR) fibrosis stage F3 or F4; either no drug/alcohol use 
for 6 months or current addiction treatment; specialist physi-
cian to prescribe DAAs; and, if HIV-infected, confirmation of 
antiretroviral therapy or HIV RNA suppression [16]. On July 1, 
2018, RI’s DAA Medicaid Restrictions were lifted under threat 
of lawsuit [17].
Variables
We conducted a chart review to obtain baseline characteris-
tics for treated patients (age, gender, payer), clinical measures 
(HCV genotype, HIV coinfection, HBV coinfection, cirrhosis, 
HCC), SVR, and reinfection. We included treatment initiation 
and reinfection data from November 1, 2014 (the first date we 
could access DAAs) through October 31, 2019, and SVR data 
through February 29, 2020. A patient is characterized as having 
cirrhosis if they fulfill any of the following: (1) liver biopsy with 
METAVIR stage 4 fibrosis; (2) presence or history of any of 
the following: ascites, spontaneous bacterial peritonitis (SBP), 
esophageal varices, hepatic encephalopathy, hepatorenal syn-
drome, hepatopulmonary syndrome; (3) presence of 2 or more 
of the following: (a) Fibrosure >0.75, (b) FIB-4 >3.25, (c) APRI 
>2, (d) platelets <140 000/mL, (e) transient elastography >12.5 
kPa, (f) imaging revealing signs of portal hypertension (spleen 
size >13 cm, portal flow mean velocity <12 cm/sec, portal vein 
mean diameter >13 mm). Decompensated cirrhosis was defined 
as presence or history of ascites, SBP, esophageal varices, hepatic 
encephalopathy, hepatorenal syndrome, hepatopulmonary syn-
drome, or HCC.
The primary outcome, SVR, was defined as undetectable 
HCV RNA 12 weeks post-EOT or at the first follow-up time 
point beyond the SVR date for patients missing this blood 
draw. SVR was marked as missing when SVR could not be con-
firmed 12 weeks post-EOT or in subsequent follow-up. HCV 
reinfection was defined as the presence of detectable HCV 
RNA following undetectable HCV RNA 12 weeks after EOT or 
genotype switch.
Ninety-four patients were treated through a research study 
providing sofosbuvir/velpatasvir (SOF/VEL). Other pa-
tients were prescribed SOF/VEL or a combination of the fol-
lowing medications consistent with society guidelines [18] 
and those accessible through each payer at the time of initial 
HCV encounter: simeprevir, sofosbuvir, daclatasvir, sofosbuvir/
ledipasvir, elbasvir/grazoprevir, SOF/VEL, SOF/VEL/
voxilaprevir, glecaprevir/pibrentasvir, and ribavirin.
Data were systematically abstracted from clinical charts, 
de-identified, and entered into an electronic database in a 
standardized process. Three authors performed data extrac-
tion, database entry, and cross-checking. Statistical analyses 
were performed using Excel, version 2016 (Microsoft). To en-
sure data accuracy, the expert clinician team member randomly 
verified collected data. Discrepancies were addressed through 
team discourse. Data were recoded as necessary.
Data Analysis
We descriptively examined patient baseline characteristics 
using counts and percentages for categorical variables. The 
continuous variable age was grouped into age range categories. 
We evaluated differences in continuous variables using 2-tailed 
t tests and assessed differences in binary categorical variables 
using the pooled z-test statistic for differences in propor-
tions. We applied the .05 alpha level for assessing statistical 
significance.
The numerator for the intention-to-treat (ITT) SVR calcu-
lation was the number of patients with undetectable HCV VL 
12 weeks post-EOT or at the first follow-up time point past this 
scheduled SVR date. The denominator consisted of all patients 
with an available SVR result (achieving or not achieving), ex-
cluded patients not yet due for SVR and patients still on treat-
ment at the end of data collection, but included patients starting 
treatment and lost to follow-up (LTFU) after initiating DAAs 
and reaching SVR.
The modified ITT (mITT) SVR numerator was calculated as 
the number of patients with undetectable HCV viral load 12 
weeks post-EOT or at the first follow-up time point past this 
scheduled SVR date. The denominator consisted of all patients 
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with available SVR results. The patients initiating treatment 
and LTFU were excluded from the denominator, as were pa-
tients not yet due for SVR and patients still on treatment. In 
the analysis of patients who did and did not achieve SVR, age 
and gender differences were compared with a 2-tailed t test and 
pooled z-test, respectively.
Reinfection rate was calculated as the number of reinfections 
divided by the at-risk person time between EOT and end of data 
collection for patients who were not reinfected, or the assumed 
date of reinfection for reinfected patients, defined as the mid-
point between EOT and the first follow-up date with detectable 
HCV RNA [19, 20]. The following sensitivity analyses were car-
ried out: At-risk person time was calculated as time between 
SVR date and the first follow-up date with detectable HCV 
RNA, and at-risk person time was calculated as time between 
SVR date and the midpoint between the SVR date and the first 
follow-up date with detectable HCV RNA [19, 20]. Median time 
to the first reinfection and interquartile range (IQR) were cal-
culated and reported in days. In the analysis of patients who 
achieved SVR and were reinfected, comparisons of patients 
who were and were not reinfected were conducted to assess age 
and gender differences using a 2-tailed t test and pooled z-test, 
respectively.
RESULTS 
Baseline Characteristics of DAA-Treated Patients
From May 1, 2014, to October 31, 2019, 426 patients under-
went initial HCV physician evaluation. Of these, 275 (64.6%) 
initiated DAAs, with a mean age (range) of 43 (22–71) years, 
34.5% female, and 57.5% genotype 1a (Table  1). Sixty-four 
(23.3%) had cirrhosis at presentation; of these, 7 (2.5%) pre-
sented with decompensated cirrhosis. Most patients, 92%, 
were Medicaid recipients, under the following Medicaid plans: 
53.1% Neighborhood Health, 26.9% United Health, 16.9% RI 
Medicaid, 4.7% Tufts Health, 0.4% Mass Health.
One patient presenting with cirrhosis was diagnosed with HCC 
shortly after initial HCV evaluation and achieved SVR and long-
term remission. A second patient presenting with cirrhosis was 
diagnosed with HCV-associated intrahepatic cholangiocarcinoma 
shortly after achieving SVR and died from this malignancy. A third 
presenting with cirrhosis was diagnosed with HCC 6 months post-
SVR. For this patient, Medicaid denied the prescription for an op-
timal regimen, approving only a shortened treatment course. The 
patient did not achieve SVR with this first DAA regimen despite 
reporting perfect adherence. He was then promptly prescribed 
and Medicaid-approved for a second treatment course with an 
extended regimen. He achieved SVR following retreatment, then 
subsequently developed HCC and died.
SVR 
Of the 275 patients who initiated DAAs, 2 were still awaiting 
SVR at the end of data collection (Figure  2). Of the 273 patients 
who were 12 weeks or more post-EOT, 232 patients had an un-
detectable HCV VL 12 weeks post-EOT or at the first follow-up 
time point past their scheduled SVR date. The ITT SVR was 
85.0% (232/273). Twenty-four patients were LTFU, meaning 
they were missing SVR results 12 weeks or more post-EOT. 
Seventeen patients did not achieve SVR. The mITT SVR was 
93.2% (232/249).
There was a difference in mean age between patients who did 
and did not achieve SVR (difference, 6.6 years; 95% CI, 1.8 to 
11.9; P < .01). Patients achieving SVR were older, with a mean 
age (range) of 44 (22–71) years; for patients not achieving SVR, 
the mean age (range) was 37 (23–55) years. No gender differ-
ences were found between patients who did and did not achieve 
SVR (difference of proportions, 2%; 95% CI, –1.3% to 1.3%; 
P = .4).
Reinfection
Of 275 patients initiating DAAs, 30 reinfections occurred 
over 375.5 person years of follow-up, for a reinfection rate of 
7.99 (95% CI, 5.1 to 10.8) per 100 person-years. The median 
time to first reinfection was 128 days, with an IQR from 85.25 
to 202.5  days. Sensitivity analyses conducted to determine 
Table 1. Demographics and Clinical Characteristics of 275 HCV-Infected 
Patients on OAT Treated for HCV
Characteristics Total Treated (n = 275)
Age, y No. (%)
 21–30 46 (16.7)
 31–40 91 (33.1)
 41–50 53 (19.3)
 51–60 54 (19.6)
 61–70 30 (10.9)
 71–80 1 (0.4)
Gender  
 F 95 (34.5)
 M 180 (65.5)
HCV genotype  
 1a 158 (57.5)
 1b 16 (5.8)
 2 17 (6.2)
 3 61 (22.2)
 4 18 (6.5)
 6 1 (0.4)
 Mixed 4 (1.5)
Other liver disease  
 HIV/HCV 4 (1.5)
 HBV/HCV 4 (1.5)
 Cirrhosis 64 (23.3)
  Compensated 57 (20.7)
  Decompensated 7 (2.5)
Insurance  
 Public 270 (98.2)
  Medicaid 253 (92.0)
  Medicare 17 (6.2)
 Private 5 (1.8)
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; OAT, opioid agonist therapy.
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whether the reinfection rate would differ under alternate def-
initions of date of reinfection revealed nearly identical results 
(not shown).
There was a difference in mean age between those who 
were and were not reinfected (difference, 4.9 years; 95% CI, 
–9.1 to –0.6; P < .01). Reinfected patients were younger, with 
a mean age (range) of 39 (25–56) years; for patients not rein-
fected, the mean age (range) was 44 (22–71) years. No gender 
differences were found between those who were and were not 
reinfected.
Treatment and Medicaid Restrictions
Seventy-two patients initiated DAAs under Medicaid restric-
tions (November 1, 2014–June 30, 2018), with mean age of 
55 (30–71  years), 26.4% female, and 69.4% having cirrhosis 
(Table 2). From July 1, 2018, to October 31, 2019, 109 patients 
initiated DAAs, with a mean age (range) of 39 (22–65) years, 
38.5% female, and 9.2% having cirrhosis. This analysis excludes 
94 patients treated through a study providing DAAs. There was 
a difference in mean age between those initiating treatment be-
fore and after lifting restrictions (difference, 15.8 years; 95% CI, 
Table 2. Characteristics of Patients Initiating DAAs Before and After Lifting Medicaid DAA Restrictions
Initiated DAAs November 2014–June 2018 Initiated DAAs July 2018–October 2019 Difference of Means,b P
Age, y n = 72,a No. (%) n = 109,a No. (%)  
 21–30 1 (1.4) 26 (23.9) <.001
 31–40 7 (7.7) 42 (38.5)
 41–50 14 (14.4) 20 (18.2)
 51–60 26 (26.1) 17 (15.6)
 61–70 23 (23.9) 4 (3.7)
 71–80 1 (1.4) –
Gender    
 F 19 (26.4) 44 (38.5) .064
 M 53 (73.6) 67 (61.5)
 Cirrhosis 50 (69.4) 10 (9.2) <.001
  Compensated 44 (61.1) 9 (8.3)
  Decompensated 6 (8.3) 1 (0.9)
Insurance    
 Public 69 (95.8) 107 (98.2)  
  Medicaid 56 (77.8) 106 (97.2)  
  Medicare 13 (18.1) 1 (0.9)  
Private 3 (4.2) 2 (1.8)  
Abbreviation: DAA, direct-acting antiviral agent.
aExcludes 94 patients treated in a study using sofosbuvir/velpatasvir.
bP values represent difference of means between the pre- and post-Medicaid restriction removal groups.
Patients initiated DAAs
N = 275 (100%)
Awaiting SVR
N = 2
Lost to follow-up
N = 24/273 (8.8%)
ITT SVR
N = 232/273 (85.0%)
mITT SVR
N = 232/249 (93.2%)
Legend
DAAs = Direct-acting antivirals
SVR = Sustained virologic response
ITT = Intent-to-treat
mITT = Modified intent-to-treat
Treatment failure
N = 17/273 (6.2%)
Figure 2. DAA treatment outcomes.
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12.6 to 19; P  <  .001). With restrictions, most treated patients 
were >50 (67.3%), while once restrictions ended, a fifth (19.8%) 
were >50. There was a difference in the proportion with cir-
rhosis between those initiating DAAs before and after removing 
restrictions (difference, –59.3%; P < .001). With restrictions, 72 
patients accessed DAAs over 3.7 years; without restrictions, 109 
patients accessed DAAs over 1.3 years.
DISCUSSION
Our findings show that people who initiated DAAs in an 
urban MMP achieved high levels of SVR. This outcome in a 
real-world setting demonstrates how effective HCV clinical 
management can be for a marginalized US population on OAT 
without access to ideal multidisciplinary care—without on-site 
primary or psychiatric care, common among US MMPs. Our 
approach incorporating colocated HCV and OAT treatment, 
HR, flexible health care delivery, and universal “test to treat” 
delivered in a resource-limited setting can inform models of 
service delivery.
Our SVR rate (85%) is comparable to those from studies 
of DAAs in similar populations. A  systematic review and 
meta-analysis of international DAA treatment outcomes re-
ports SVR of 87.4% among people with recent IDU and 90.7% 
among those receiving OAT [2]. An even more recent prospec-
tive, open-label, observational trial at an HR organization in 
Washington DC reports SVR of 82% among 100 patients with 
OUD and ongoing IDU treated with SOF/VEL and offered con-
current buprenorphine initiation [21]. Two US retrospective 
evaluations of real-world colocated care reported SVR rates of 
85% among 300 homeless-experienced individuals in Boston, 
Massachusetts, treated at a Federally Qualified Health Center 
providing integrated primary care and among 75 patients 
treated at a New Haven, Connecticut, not-for-profit addiction 
treatment program providing OAT with on-site primary and 
psychiatric care [19, 22].
Another success of this “real-world” cohort was the low pro-
portion loss to follow-up and patients evaluable for SVR (8.8% 
of the ITT population). Engagement following DAA therapy is 
necessary for determining SVR, managing cirrhosis, ongoing 
HR, routine testing for reinfection, and prompt retreatment 
[23]. Colocated OAT can improve retention in HCV care [22]. 
This may signify the HCV team’s experience in OUD, may re-
flect patients’ possible lack of a medical home, and/or may be 
a consequence of patients being pharmacologically wedded 
to OAT.
The SVR rate and low proportion lost to follow-up in the 
absence of robust colocated ambulatory services could also 
reflect the support and organization built into other aspects 
of MMP care. MMPs are tightly structured, complex environ-
ments [15]. Following a physician assessment, patients ingest 
a daily methadone dose under direct nursing observation. 
Results of toxicology screens and compliance with behavioral 
parameters dictate the number of carry-home doses, which 
reduce the frequency of clinic attendance. This infrastruc-
ture may be leveraged for HCV care, which is important given 
the high HCV prevalence at MMPs and failure of off-site re-
ferral (Figure  3) [24]. Comfortable, compassionate care can 
be provided by staff cognizant of and working to ameliorate 
Medical care
Leveraging OATP infrastructure for on-site HCV care
Prevention
HCV universaol “Test to Treat” Infectious disease care
Services
Frequent attendanceSupportive environment
for HCV treatment
• Primary care
• Psychiatry
• Harm reduction (NSP, naloxone)
• HIV PreP
• HAV & HBV vaccinations
• Staff  familiar with psychosocial needs
• Low threshold care
• Counseling
• Peer support
• Housing/employment assistance
• Universal, opt-out HCV screening
• Accelerated, streamlined care
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Figure 3. Leveraging MMP infrastructure for on-site HCV care.
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the hardships faced by clients contending with OUD. Nursing 
services, peer support, mental health care and housing assis-
tance may be offered. Regular contact presents opportunity 
for everyday support and time for development of therapeutic 
relationships. 
Conversely, there are problems with MMPs. Methadone is 
the most common form of OAT in the United States [25]. The 
US federal 1974 Narcotic Addict Treatment Act mandated that 
patients attend a federally licensed clinic for methadone main-
tenance [15]. This created an MMP system outside of main-
stream health care, in which medical standards of care are not 
always fully incorporated, care beyond dispensing methadone 
may be limited, and patients are ghettoized with patients with 
the same diagnosis [15].
The reinfection rate observed in this study is similar to that 
of other cohorts of PWID on OAT in the DAA era with on-
going IDU. Data are limited on reinfection rates among patients 
on OAT post-DAA therapy in the United States. Among a New 
York cohort of PWID on OAT, incidence of reinfection was 7.4 
per 100 person-years among those reporting ongoing IDU [6]. 
In a recent meta-analysis, the reinfection rate was 5.9 per 100 
person-years among PWID receiving OAT with recent drug 
use [26]. Near Rhode Island, among a homeless population in 
Boston, Massachusetts, the reinfection rate was 13.1 per 100 
person-years [19].
CODAC Providence is situated in a hotspot of drug ac-
tivity and overdose. NSP is available nearby but not on-site. 
Mounting fentanyl and methamphetamine use may con-
tribute to more frequent injecting behavior. While OAT 
curtails opioid use, it does not hinder use of stimulants, 
benzodiazepines, or alcohol, and its efficacy can be com-
promised by use of these substances. An insufficient number 
of RI providers prescribing DAAs to drug-involved popu-
lations and slow scale-up of HCV treatment may also con-
tribute to reinfection.
The timing of this evaluation highlights the impact of re-
moving DAA restrictions. At program inception, we prioritized 
older patients, those at risk for advanced fibrosis, and those who 
were better able to access DAAs under fibrosis restrictions [27]. 
We were unable to treat HCV before progression to advanced 
fibrosis—typically in younger patients, often the transmitting 
population. The remaining US DAA restrictions should be 
abolished.
Adding a pharmacist to our team, along with ending DAA 
restrictions, supported treating more people in the year after 
restrictions ended than in the 4 years prior. The time- and la-
bor-intensive PA processes remain a modifiable barrier to 
expanding treatment capacity as we aim for test to treat with 
same-day DAA initiation. It is time to eliminate the DAA 
PA process. Without the PA process, or with a simplified PA 
process, the pharmacist could undertake more clinical respon-
sibilities such as treatment initiation visits, adherence support, 
and follow-up coordination and ultimately help expand treat-
ment capacity.
The Veterans Administration (VA) is the largest provider of 
HCV care in the United States. Their successful elimination 
strategy includes pharmacist-led HCV management, an ap-
proach utilized globally. By 2017, one-fourth of VA DAA pre-
scriptions were initiated by a network of 200 pharmacists [28]. 
Enabling community pharmacists—highly educated, under-
utilized health care workers—to prescribe DAAs with physician 
collaboration for patients with advanced liver disease is another 
key strategy to expand US treatment capacity.
This study has several limitations. It is from a single insti-
tution, retrospective, and limited to data collected within the 
context of routine clinical care. We lack a viral hepatitis sur-
veillance system. We do not have data on the total number of 
patients screened and diagnosed with HCV. We only had staff 
to enter detailed data for patients prescribed DAAs. While de-
lays in obtaining SVR testing were common, we did not record 
the date of actual SVR. We do not have data on the untreated 
population, nor on patient-level factors possibly associated 
with lack of SVR or reinfection, such as ongoing substance use 
and polysubstance use, mean OAT dose, or housing status. To 
strengthen respect and trust, we do not collect data on ongoing 
substance use, nor do we access the methadone clinic electronic 
health record (EHR), which contains this information. We work 
to develop system-level enhancements to overcome individual 
baseline characteristics. Most patients receive methadone main-
tenance, with a small minority prescribed buprenorphine/nal-
oxone (Medicaid patients could not access buprenorphine until 
2016); we do not have data on the exact percentage.
CONCLUSIONS
DAA treatment is effective among patients with OUD receiving 
colocated HCV care in a US resource-limited inner-city MMP. 
“One-stop shopping” with simplified pretreatment assessment 
and serum biomarkers to stage fibrosis accelerates the path to 
cure. Eliminating the PA process and remaining state DAA re-
strictions will expedite treatment initiation following diagnosis 
to reduce viremic time and incidence.
How can we incorporate HCV management into over 1600 
US MMPs [29]? Financial challenges are a limiting factor. US 
health insurance and payment systems poorly reimburse HCV 
outpatient care. Models that improve the business case for HCV 
management without income from procedural billing for en-
doscopy, colonoscopy and radiology are needed to achieve fi-
nancial sustainability at MMPs. Extending state and federal 
support for OUD to support HCV care would help. Virtual 
colocation via telemedicine can aid in HCV treatment rollout. 
Telemedicine imports HCV management into locales conven-
ient for and familiar to patients, but lacking HCV expertise, in-
frastructure, and resources [30].
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Determining the essential components of colocated OAT/
HCV care to optimize outcomes requires additional study. To 
mitigate the syndemic of HCV and addiction, alternative pay-
ment and financing sources must be identified.  Methadone 
must become more accessible across a range of clinical settings 
including primary care and community pharmacies, while the 
full spectrum of HCV services should be offered on-site at OAT 
programs via a holistic, patient-centered approach that best 
meets the needs of drug-involved populations.
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